​

CG Oncology (CGON) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CGON Stock Forecast

CG Oncology (CGON) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $79.00, with a high of $93.00 and a low of $70.00. This represents a 22.18% increase from the last price of $64.66.

$25 $39 $53 $67 $81 $95 High: $93 Avg: $79 Low: $70 Last Closed Price: $64.66

CGON Stock Rating

CG Oncology stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

CGON Price Target Upside V Benchmarks

TypeNameUpside
StockCG Oncology22.18%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-713
Avg Price Target-$78.29$74.23
Last Closing Price$64.66$64.66$64.66
Upside/Downside-21.08%14.80%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26411---15
Feb, 26411---15
Jan, 26411---15
Dec, 25410---14
Nov, 2558---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 10, 2026Truist Financial$75.00$53.3940.48%15.99%
Jan 21, 2026RBC Capital$73.00$54.6933.48%12.90%
Jan 16, 2026Kelsey GoodwinPiper Sandler$70.00$53.0731.90%8.26%
Jan 12, 2026Goldman Sachs$82.00$54.2051.29%26.82%
Jan 09, 2026Morgan Stanley$93.00$54.2071.59%43.83%
Jan 09, 2026Truist Financial$66.00$54.1821.82%2.07%
Jan 08, 2026Sean LaamanMorgan Stanley$89.00$42.09111.45%37.64%
Dec 11, 2025Wedbush$70.00$41.3069.49%8.26%
Nov 24, 2025Gregory RenzaTruist Financial$62.00$42.4446.09%-4.11%
Nov 17, 2025RBC Capital$61.00$41.0148.74%-5.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 16, 2026Piper SandlerOverweightOverweighthold
Jan 12, 2026Goldman SachsBuyBuyhold
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Dec 11, 2025WedbushOutperforminitialise
Nov 17, 2025RBC CapitalOutperformOutperformhold
Oct 07, 2025GuggenheimBuyinitialise
Aug 18, 2025Piper SandlerOverweightinitialise
Jan 10, 2025H.C. WainwrightBuyBuyhold
Oct 24, 2024UBSBuyinitialise

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.02$-1.41$-2.08---
Avg Forecast$-1.33$-1.28$-1.76$-1.40$-1.20$0.67
High Forecast$-1.15$-1.21$-1.51$-0.02$-0.02$1.34
Low Forecast$-1.43$-1.37$-1.99$-2.77$-2.39$0.01
Surprise %-23.31%10.16%18.18%---

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$204.00K$1.14M$4.04M---
Avg Forecast$100.75K$1.28M$3.49M$99.15M$175.75M$395.91M
High Forecast$177.20K$2.15M$6.15M$174.38M$309.11M$696.33M
Low Forecast$24.30K$409.27K$842.88K$23.92M$42.39M$95.50M
Surprise %102.48%-11.05%15.61%---

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.61M$-88.04M$-161.00M---
Avg Forecast$-5.77M$-5.54M$-7.60M$-6.04M$-5.21M$2.91M
High Forecast$-4.97M$-5.24M$-6.53M$-81.98K$-70.66K$5.79M
Low Forecast$-6.17M$-5.92M$-8.64M$-12.00M$-10.35M$39.52K
Surprise %742.27%1488.98%2017.07%---

CGON Forecast FAQ

Is CG Oncology stock a buy?

CG Oncology stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that CG Oncology is a favorable investment for most analysts.

What is CG Oncology's price target?

CG Oncology's price target, set by 9 Wall Street analysts, averages $79 over the next 12 months. The price target range spans from $70 at the low end to $93 at the high end, suggesting a potential 22.18% change from the previous closing price of $64.66.

How does CG Oncology stock forecast compare to its benchmarks?

CG Oncology's stock forecast shows a 22.18% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CG Oncology over the past three months?

  • March 2026: 26.67% Strong Buy, 73.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 26.67% Strong Buy, 73.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 26.67% Strong Buy, 73.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is CG Oncology’s EPS forecast?

CG Oncology's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.4, marking a -32.69% decrease from the reported $-2.08 in 2025. Estimates for the following years are $-1.2 in 2027, and $0.67 in 2028.

What is CG Oncology’s revenue forecast?

CG Oncology's average annual revenue forecast for its fiscal year ending in December 2026 is $99.15M, reflecting a 2354.17% increase from the reported $4.04M in 2025. The forecast for 2027 is $175.75M, and $395.91M for 2028.

What is CG Oncology’s net income forecast?

CG Oncology's net income forecast for the fiscal year ending in December 2026 stands at $-6.042M, representing a -96.25% decrease from the reported $-161M in 2025. Projections indicate $-5.208M in 2027, and $2.91M in 2028.